Evidence map›Paper›PMID 38806543›Full record

ArticleScientific reports2024

PMMA dialyzers modulate both humoral and cell-mediate immune response to anti-COVID-19 vaccine (BNT162b2) in a cohort of chronic hemodialyzed patients.

Giuseppe Castellano, Giuseppe Stefano Netti, Vincenzo Cantaluppi, Vincenzo Losappio, Federica Spadaccino, Elena Ranieri, Marita Marengo, Maurizio Borzumati, Carlo Alfieri, Giovanni Stallone

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giuseppe CastellanoNephrology, Dialysis and Renal Transplantation Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Via Commenda 15, 20122, Milan, Italy. giuseppe.castellano@unimi.it.
Giuseppe Stefano NettiUnit of Clinical Pathology, Center for Molecular Medicine and Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Vincenzo CantaluppiUnit of Nephrology and Kidney Transplantation, Department of Translational Medicine, University of Piemonte Orientale (UPO), 17-28100, Novara, Italy.
Vincenzo LosappioUnit of Nephrology Dialysis and Transplantation, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Federica SpadaccinoUnit of Clinical Pathology, Center for Molecular Medicine and Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Elena RanieriUnit of Clinical Pathology, Center for Molecular Medicine and Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Marita MarengoUnit of Nephrology and Dialysis, Azienda Sanitaria Locale (ASL) CN1, Cuneo, Italy.
Maurizio BorzumatiUnit of Nephrology and Dialysis, ASL VCO, Verbania, Verbano Cusio Ossola, Italy.
Carlo AlfieriNephrology, Dialysis and Renal Transplantation Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Via Commenda 15, 20122, Milan, Italy.
Giovanni StalloneUnit of Nephrology Dialysis and Transplantation, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients on hemodialysis (HD) have a high risk of death from COVID-19. We evaluated the humoral and cell-mediated immune response to BNT162b2 (Pfizer-BioNTech) vaccine in HD patients, comparing HD with Poly-methyl-methacrylate (PMMA) and HD with Polysulphone (PS). Samples were collected before vaccination (T0) and 14-days after the 2ndvaccine (T2) in a TG (TG, n = 16-Foggia) and in a VG (CG, n = 36-Novara). Anti-SARS-CoV-2-Ig were titrated in the cohort 2-weeks after the 2nddose of vaccine. In the Testing-Group, serum neutralizing antibodies (NAb) were assayed and PBMCs isolated from patients were thawed, counted and stimulated with SARS-CoV-2 IGRA stimulation tube set. All patients had a positive ab-response, except in a case. PMMA-patients had higher levels of anti-SARS-CoV-2 IgG (p = 0.031); VG data confirmed these findings (p < 0.05). NAb evaluation: PMMA patients passed the positive cut-off value, while in PS group only only 1/8 patient did not respond. PMMA patients showed higher percentages of anti-SARS-CoV-2 S1/RBD-Ig after a complete vaccine schedule (p = 0.028). Interferon-gamma release: PMMA patients showed significantly higher release of IFNγ (p = 0.014). The full vaccination course provided sufficient protection against SARS-CoV-2 across the entire cohort, regardless of dialyzer type. After vaccination, PMMA patients show a better immune response, both humoral and cellular, at the end of the vaccination course than PS patients.

Indexed as

Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19Immunity, CellularImmunity, HumoralPolymethyl MethacrylateRenal DialysisSARS-CoV-2AgedAged, 80 and overCohort StudiesCOVID-19 VaccinesFemaleHumansImmunoglobulin GAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GPolymersPolymethyl Methacrylatepolysulfone P 1700SulfonesCellular immunityHemodialysis patientsHumoral immunityPoly-methyl-methacrylateSARS-CoV-2 vaccinationVaccine antibody response

Identifiers

PMID38806543
PMCPMC11133365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.